GlassScriptPhysician profile
Philip Almalouf
NPI 1407976129
$14,391.49
in general payments reported to CMS, 2019-2025
48 companies · $3,278 in 2025
The $3,278 reported for 2025 was more than what 84% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,605 · 2020: $907 · 2021: $1,156 · 2022: $1,879 · 2023: $1,996 · 2024: $2,570 · 2025: $3,278.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,354 · Education: $291 · Consulting Fee: $200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,354.14 |
| Education | $290.57 |
| Consulting Fee | $200.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $2,520.79 | 2019-2025 | Uptravi, Opsumit, Opsynvi |
| United Therapeutics Corporation | $2,477.34 | 2019-2025 | Tyvaso, Tyvaso, Remodulin |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,274.36 | 2019-2025 | Ofev, Jascayd, Stiolto Respimat |
| Regeneron Healthcare Solutions, INC. | $878.79 | 2020-2025 | Dupixent |
| Astrazeneca Pharmaceuticals LP | $815.60 | 2019-2025 | Tezspire, Fasenra, Farxiga |
| Genzyme Corporation | $812.46 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $707.07 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $629.13 | 2019-2024 | Uptravi |
| Merck Sharp & Dohme LLC | $604.47 | 2019-2025 | Winrevair, Zerbaxa, Dificid |
| Electromed, INC. | $542.15 | 2019-2025 | Smartvest |
| Glaxosmithkline, LLC. | $314.69 | 2019-2025 | Nucala, Trelegy Ellipta |
| Mallinckrodt Hospital Products INC. | $291.19 | 2020-2025 | Acthar |
| Astellas Pharma US INC | $212.87 | 2019-2022 | |
| Mylan Specialty L.P. | $210.99 | 2019-2024 | Yupelri |
| Grifols USA, LLC | $191.59 | 2019-2020 |
Show all 48 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sandoz INC. | $177.67 | 2019-2025 | Treprostinil |
| Philips North America LLC | $176.78 | 2019-2025 | Vest Therapy Und, (Ak6) Vest Therapy |
| Sunovion Pharmaceuticals INC. | $160.99 | 2019 | |
| Alexion Pharmaceuticals, INC. | $145.18 | 2019-2023 | Ultomiris |
| Gilead Sciences, INC. | $124.73 | 2019-2022 | |
| La Jolla Pharmaceutical Company | $93.07 | 2022 | |
| Ani Pharmaceuticals, INC. | $88.50 | 2023-2025 | Purified Cortrophin Gel |
| Abbvie INC. | $87.30 | 2023-2025 | Teflaro |
| Mallinckrodt Enterprises LLC | $82.49 | 2019 | |
| Viatris Specialty LLC | $65.50 | 2025 | Yupelri |
| Pulmonx Corporation | $64.44 | 2024 | Chartis Catheter, Zephyr Endobronchial Valve, Pulmonx Chartis Tablet Console |
| Genentech USA, INC. | $61.41 | 2019-2020 | |
| Abiomed | $51.68 | 2023-2024 | Impella |
| Inogen, INC. | $50.28 | 2023 | Inogen One G5 Oxygen Concentrator - Bluetooth |
| Circassia INC. | $49.20 | 2019 | |
| Allergan, INC. | $44.86 | 2019 | |
| Mannkind Corporation | $44.84 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $40.18 | 2019-2021 | |
| Insmed, INC. | $37.16 | 2021-2025 | Arikayce |
| Portola Pharmaceuticals, LLC | $33.26 | 2019-2020 | |
| Pfizer INC. | $26.59 | 2019-2024 | |
| Liquidia Technologies, INC. | $22.96 | 2025 | Yutrepia |
| Jazz Pharmaceuticals INC. | $20.54 | 2023 | |
| Novartis Pharmaceuticals Corporation | $19.39 | 2019 | |
| Shire North American Group INC | $19.06 | 2019 | |
| Shionogi INC | $18.95 | 2023 | Fetroja |
| Sanofi Pasteur INC. | $16.84 | 2019 | |
| Chiesi USA, INC. | $16.84 | 2021 | |
| Csl Behring | $15.76 | 2019 | |
| Corcept Therapeutics | $14.54 | 2021 | |
| Veran Medical Technologies, INC. | $13.35 | 2019 | |
| Covidien LP | $11.92 | 2020 | |
| Lilly USA, LLC | $11.74 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Philip Almalouf listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.